Search
Now showing items 461-470 of 508
Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work.
(WILEY, 2019-04-01)
While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging, pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify and randomise ...
The shieldin complex mediates 53BP1-dependent DNA repair.
(NATURE PUBLISHING GROUP, 2018-08-02)
53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini1,2. This function of 53BP1 requires interactions with PTIP3 and RIF14-9, ...
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
(BMC, 2022-09-15)
BACKGROUND: Renal cell carcinoma (RCC) is a heterogeneous disease comprising histologically defined subtypes. For therapy selection, precise subtype identification and individualized prognosis are mandatory, but currently ...
The use of digital pathology and image analysis in clinical trials.
(WILEY, 2019-04-01)
Digital pathology and image analysis potentially provide greater accuracy, reproducibility and standardisation of pathology-based trial entry criteria and endpoints, alongside extracting new insights from both existing and ...
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
(SPRINGERNATURE, 2023-11-08)
Mesothelioma is an aggressive cancer of the mesothelial layer associated with an extensive fibrotic response. The latter is in large part mediated by cancer-associated fibroblasts which mediate tumour progression and poor ...
Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.
(SPRINGER BASEL AG, 2018-11-01)
Gastric cancer is one of the most aggressive malignancies, with limited treatment options in both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic characterization, stomach tumour has ...
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
(OXFORD UNIV PRESS, 2018-05-01)
BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
Detecting truly clonal alterations from multi-region profiling of tumours.
(NATURE PORTFOLIO, 2017-03-27)
Modern cancer therapies aim at targeting tumour-specific alterations, such as mutations or neo-antigens, and maximal treatment efficacy requires that targeted alterations are present in all tumour cells. Currently, treatment ...
Cancer associated fibroblast FAK regulates malignant cell metabolism.
(NATURE PUBLISHING GROUP, 2020-03-10)
Emerging evidence suggests that cancer cell metabolism can be regulated by cancer-associated fibroblasts (CAFs), but the mechanisms are poorly defined. Here we show that CAFs regulate malignant cell metabolism through ...